Follicular Lymphoma
Conditions
Keywords
Follicular lymphoma, Rituximab, Autologous dendritic cells, Cancer vaccine
Brief summary
Patients with non-curable disseminated follicular lymphoma receive local radiotherapy targeting single lymph nodes and injection of low-dose rituximab (anti-CD20) and autologous dendritic cells. The therapy is repeated 3 times, targeting different lesion. Aims are to induce tumor immunity and clinical responses.
Detailed description
The clinical protocol is based on the rationale that the immune system has been developed to combat infectious disease. To mimic the environment in infected tissue, selected tumor-affected lymph nodes are treated locally with a single dose of 8 Gy radiotherapy and injected with therapeutic antibody (anti-CD20/Rituximab). Later, dendritic cells (DC) are injected into the damaged tumor tissue together with a stimulatory cytokine (GM-CSF) to initiate an immune response. Patients with untreated or relapsed stage III/IV follicular lymphoma not in need of standard therapy receive intra-tumoral injections of low-dose anti-CD20 antibodies (5 mg) on days 1 and 3 and local radiotherapy on day 2. On days 4 and 5, dendritic cells generated from monocytes isolated from the patients blood are injected into the site together with the stimulatory cytokine GM-CSF administered subcutaneously. Additional lymph nodes are treated similarly after 2 and 4 weeks. The treatment is thus performed three times, targeting different lymphoma nodes. The primary aims are to induce tumor-specific immune responses and clinical responses.
Interventions
BIOLOGICALRadiotherapy, rituximab and DC
Lymphoma lymph nodes are irradiated with 8 Gy single treatment and injected with rituximab (5 mg) and autologous DC intratumorally. The treatment is performed 3 times targeting different lymph nodes
Sponsors
Norwegian Cancer Society
Helse Sor-Ost
Oslo University Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age 18 years and older 2. Histologically confirmed (by WHO classification) untreated and relapsed indolent non-Hodgkin's B-cell lymphoma of low-grade follicular, marginal zone, lymphoplasmocytic or small lymphocytic subtypes. 3. Stage III/IV 4. Adequate bone marrow function (leukocyte count\>2,0, neutrophil count\>1.0, platelets\>50) 5. Two or more separate lymph nodes \> 1,5 cm available for biopsy or treatment. 6. Measurable disease present other than biopsy site and injection site(s). 7. Required wash-out period after previous treatment: Chemotherapy - 8 weeks, Radiotherapy - 4 weeks, Rituximab - 12 weeks 8. WHO status 0-1 9. Life expectancy of more than 6 months 10. Written informed consent 11. Able to comply with the treatment protocol -
Exclusion criteria
1. Patients with progressive lymphoma in need of systemic therapy or standard dose irradiation. 2. Chronic bacterial, viral or fungal infection 3. Pre-existing autoimmune or antibody mediated disease including: systemic lupus, erythematosus, rheumatoid arthritis, multiple sclerosis, Sjogren's syndrome, autoimmune thrombocytopenia, but excluding controlled thyroid disease, or the presence of autoantibodies without clinical autoimmune disease. 4. Known history of HIV 5. Central nervous system involvement of lymphoma 6. Current anticoagulant therapy which can not safely be paused during treatment injections (ASA \< 325 mg/day allowed) 7. Pregnancy -
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Response rate | 5 years | Clinical response measured by CT and PET/CT and immune response |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Immune response | 1 year | Immune response measured by flow cytometry. Peripheral blood mononuclear cells before and after treatment are cultures along with autologous tumor cells. Proliferation is measured. |
Countries
Norway
Outcome results
None listed